The sickle cell disease treatment market is experiencing substantial growth, projected to achieve an impressive Compound Annual Growth Rate (CAGR) of 21%. By 2032, the market value is anticipated to surpass US$ 16.9 billion. This significant growth is attributed to advancements in treatment options and increasing awareness about sickle cell disease, driving the demand for innovative therapies and boosting market expansion.
The report “Sickle Cell Disease Treatment Market, By Treatment Modality (Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy (Hydroxyurea, Branded Products {Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYNDN (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, and FT-4202})), By End-Users (Hospitals, Specialty Clinics, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”
Sample link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3832
Key Highlights:
• In December 2021, UCSF Benioff Children’s Hospital Oakland has received largest research trial grant of $17M to launch an innovative clinical trial with four year study by using CRISPR-Cas9 gene-editing technology to cure (SCD) sickle cell disease.
• In June 2021, Ministry of Tribal Affairs organized second National Conclave on Sickle Disease in India on world Sickle Cell on 19th June, 2021 in partnership with Novartis, FICCI, Apollo Hospitals, Piramal Foundation, GASCDO and NASCO with launch of “Unmukt” project to eliminate SCD (sickle cell disease). The event brought together a group of experts on SCD across India to deliberate on recent advancement in Sickle Cell Disease management with early diagnosis to latest medicine and advancement in treatment of SCD.
Analyst view:
From an analyst's perspective, the global sickle cell disease treatment market presents promising opportunities for growth. The projected remarkable CAGR of 21% and the anticipated market value of over US$ 16.9 billion by 2032 indicate a positive trend in the industry. Advancements in treatment options, including gene therapies and targeted medications, are likely to drive market expansion. Additionally, the increasing awareness about sickle cell disease among healthcare professionals and the general public is expected to lead to early diagnosis and improved patient outcomes. However, it's essential to closely monitor regulatory developments and potential challenges related to access and affordability, which could impact market dynamics. Overall, the outlook for the sickle cell disease treatment market remains optimistic, and stakeholders should focus on research and innovation to capitalize on this growth opportunity.
Competitive Landscape & their strategies of Sickle Cell Disease Treatment Market:

The prominent players operating in the Sickle Cell Disease Treatment Market includes, Baxter, Bluebird Bio, Bristol-Myers Squibb Company, Eli Lilly, Global Blood Therapeutics, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Mast Therapeutics, Novartis AG, Pfizer, Inc., Sanofi and others. The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

To know more
Contact Us:
Sales
Prophecy Market Insights
U.S. 1 860 531 2574
RoW: 917775049802
Email- [email protected]
Website- www.prophecymarketinsights.com
Blog- www.prophecyjournals.com